Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
protease inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
2000 |
| gptkbp:ATCCode |
J05AE06
|
| gptkbp:brand |
gptkb:Kaletra
|
| gptkbp:CASNumber |
192725-17-0
|
| gptkbp:combines |
gptkb:Ritonavir
|
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:developedBy |
1990s
|
| gptkbp:discoveredBy |
gptkb:Abbott_Laboratories
|
| gptkbp:drugClass |
antiretroviral therapy
|
| gptkbp:eliminationHalfLife |
5-6 hours
|
| gptkbp:hasMolecularFormula |
C37H48N4O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lopinavir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 protease
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
98-99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea hepatotoxicity hyperlipidemia |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:J05AE
|
| gptkbp:bfsLayer |
6
|